Braidwell LP Invests $26.38 Million in Avalyn Pharma Inc. $AVLN

Key Points

• Braidwell LP acquired 801,395 shares of Avalyn Pharma during the second quarter, investing approximately $26.38 million for an estimated 1.81% stake. Bank of New York Mellon also purchased a new position worth about $1.32 million.
• Avalyn Pharma reported a quarterly loss of $0.98 per share, beating analysts’ estimate of a $1.03 loss. Analysts expect a full-year loss of approximately $3.81 per share.
• Analyst opinions are mixed, but the stock carries a consensus “Moderate Buy” rating with an average price target of $60, compared with shares opening at $35.58.

Braidwell LP bought a new stake in Avalyn Pharma Inc. (NASDAQ:AVLN - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 801,395 shares of the company's stock, valued at approximately $26,382,000. Braidwell LP owned approximately 1.81% of Avalyn Pharma as of its most recent SEC filing.

Separately, Bank of New York Mellon Corp purchased a new stake in Avalyn Pharma in the 2nd quarter valued at approximately $1,321,000.

Avalyn Pharma Trading Up 0.9%

Shares of AVLN opened at $35.58 on Thursday. Avalyn Pharma Inc. has a 12-month low of $24.15 and a 12-month high of $40.17. The firm has a market capitalization of $1.58 billion and a PE ratio of -1.56. The company has a current ratio of 33.12, a quick ratio of 33.12 and a debt-to-equity ratio of 0.04. The business's 50-day simple moving average is $32.02.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.05. As a group, analysts forecast that Avalyn Pharma Inc. will post -3.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on AVLN shares. Evercore started coverage on Avalyn Pharma in a report on Tuesday, May 26th. They issued an "outperform" rating and a $51.00 price target for the company. Weiss Ratings initiated coverage on Avalyn Pharma in a research report on Thursday, August 13th. They issued a "sell (d+)" rating for the company. Guggenheim began coverage on Avalyn Pharma in a report on Monday, May 25th. They issued a "buy" rating and a $80.00 target price for the company. Zacks Research upgraded shares of Avalyn Pharma to a "hold" rating in a research report on Wednesday, May 27th. Finally, Wall Street Zen cut shares of Avalyn Pharma from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Avalyn Pharma currently has a consensus rating of "Moderate Buy" and an average target price of $60.00.

Avalyn Pharma Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.

Want to see what other hedge funds are holding AVLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avalyn Pharma Inc. (NASDAQ:AVLN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source